

SPECIAL AUTHORIZATION REQUEST FORM

Please complete all required sections to allow your request to be processed.

Patients may or may not meet eligibility requirements as established by Alberta government sponsored drug programs.

PATIENT INFORMATION				COVERAGE TYPE	
LAST NAME		FIRST NAME		INITIAL	<input type="checkbox"/> Alberta Blue Cross <input type="checkbox"/> Alberta Human Services <input type="checkbox"/> Other _____
BIRTH DATE (YYYY-MM-DD)		ALBERTA PERSONAL HEALTH NUMBER			
ADDRESS		CITY	PROV	POSTAL CODE	
					ID/CLIENT/COVERAGE NUMBER
PRESCRIBER INFORMATION					
PRESCRIBER LAST NAME		FIRST NAME		INITIAL	PRESCRIBER PROFESSIONAL ASSOCIATION REGISTRATION
ADDRESS					<input type="checkbox"/> CPSA <input type="checkbox"/> ACO REGISTRATION NUMBER <input type="checkbox"/> CARNA <input type="checkbox"/> ADA+C <input type="checkbox"/> ACP <input type="checkbox"/> Other
CITY, PROVINCE				PHONE	FAX
POSTAL CODE				FAX NUMBER MUST BE PROVIDED WITH EACH REQUEST SUBMITTED	
Please provide the following information for ALL requests					
Requested drug <input type="checkbox"/> Dupixent <input type="checkbox"/> Fasenra <input type="checkbox"/> Nucala <input type="checkbox"/> Tezspire				Dosage and Frequency	
Diagnosis <input type="checkbox"/> Severe Asthma → <input type="checkbox"/> Eosinophilic <input type="checkbox"/> Type 2 asthma (dupilumab for pediatric patients aged 6-11 only) <input type="checkbox"/> Other (please specify) _____				Please indicate if this patient is <input type="checkbox"/> Starting drug upon approval complete section I <input type="checkbox"/> New to coverage but currently maintained on drug ... complete section I and II <input type="checkbox"/> Renewing coverage complete section II	
For patients new to coverage and already on the requested drug, specify start date (YYYY-MM-DD) _____					
Section I: Please provide pre-treatment information for NEW requests for treatment-naïve and treatment-experienced patients					
1) For benralizumab, dupilumab, mepolizumab: Blood eosinophil count _____ (cells/mcL) Date _____					
2) Number* of clinically significant exacerbations of asthma within the 12-month period prior to starting the requested drug (defined as worsening of asthma such that the treating physician elected to administer systemic glucocorticoids for at least three days or the patient visited an emergency department or was hospitalized) _____ *Please provide an <u>exact</u> number. If the patient has had no exacerbations it should be reported as 'zero (0)'.					
3) Pre-treatment Asthma Control Questionnaire (ACQ-5) score _____ Date _____					
4) Previous medications utilized: Check all that apply and include name of medication, dose, duration and response <input type="checkbox"/> Inhaled corticosteroids _____ → Specify dose <input type="checkbox"/> High-dose <input type="checkbox"/> Medium-dose <input type="checkbox"/> For adults and adolescents aged 12 and older, oral corticosteroids (OCS) _____ → Patient requires daily maintenance OCS prior to initiation of requested drug? <input type="checkbox"/> Yes <input type="checkbox"/> No <input type="checkbox"/> Other asthma controllers (e.g. long-acting beta-2 agonist, please specify) _____					
Section II: Complete the following for all RENEWAL requests and INITIAL requests for treatment experienced patients					
1) Number* of clinically significant asthma exacerbations within the previous 12-month period while on the requested drug (defined as worsening of asthma such that the treating physician elected to administer systemic glucocorticoids for at least three days or the patient visited an emergency department or was hospitalized) _____ *Please provide an <u>exact</u> number. If the patient has had no exacerbations it should be reported as 'zero (0)'.					
2) Current Asthma Control Questionnaire (ACQ-5) score _____ Date _____					
3) For patients requiring daily maintenance OCS prior to initiation of requested drug ONLY, check if the following applies: <input type="checkbox"/> A decrease in the daily maintenance OCS dose from pre-treatment baseline <u>in the first 12 months of treatment</u> <input type="checkbox"/> The reduction in the daily maintenance OCS dose achieved <u>after the first 12 months of treatment</u> has at least been maintained					
Additional information relating to request (if a switch to a different drug is requested, please indicate the reason for switch):					
PRESCRIBER'S SIGNATURE		DATE (YYYY-MM-DD)		Please forward this request to Alberta Blue Cross, Clinical Drug Services 10009 108 Street NW, Edmonton, Alberta T5J 3C5 FAX 780-498-8384 in Edmonton • 1-877-828-4106 toll free all other areas	
ONCE YOUR REQUEST HAS SUCCESSFULLY TRANSMITTED, PLEASE DO NOT MAIL OR RE-FAX YOUR REQUEST.					

